A phase I first-in-human study of enoticumab (REGN421), a fully human delta-like ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors

Clinical Cancer Research

Volumn 21, Issue 12, 2015, Pages 2695-2703

  Chiorean, Elena Gabriela ^a,b   LoRusso, Patricia ^c   Strother, Robert Matthew ^b   Diamond, Jennifer R ^d   Younger, Anne ^b   Messersmith, Wells A ^d   Adriaens, Lieve ^e   Liu, Liming ^e   Kao, Richard J ^e   DiCioccio, Albert Thomas ^e   Kostic, Ana ^e   Leek, Russell ^f   Harris, Adrian ^f   Jimeno, Antonio ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e REGENERON PHARMACEUTICALS INC   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; ASPARTATE AMINOTRANSFERASE; BETA CATENIN; BRAIN NATRIURETIC PEPTIDE; CD31 ANTIGEN; ENOTICUMAB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; TROPONIN I; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN; REGN421; SIGNAL PEPTIDE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BACKACHE; BILE DUCT CARCINOMA; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COLORECTAL CANCER; CONFERENCE PAPER; CONSTIPATION; COUGHING; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENDOMETRIOID CARCINOMA; FAMILIAL COLON POLYPOSIS; FATIGUE; FEMALE; FEVER; GENE MUTATION; HEAD AND NECK CANCER; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; IMMUNOGENICITY; INSOMNIA; LIVER CELL CARCINOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOUTH CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PULMONARY HYPERTENSION; SALIVARY GLAND CANCER; SARCOMA; SOLID TUMOR; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR SUPPRESSOR GENE; VAGINA BLEEDING; VOLUME OF DISTRIBUTION; VOMITING; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; HISTORY; MIDDLE AGED; MORTALITY; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HISTORY, ANCIENT; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; TREATMENT OUTCOME;

EID: 84939779295     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2797     Document Type: Conference Paper

References (30)

1. Thurston G, Kitajewski J. VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer 2008;99:1204-9.
2. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010;16: 3141-52.
3. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011;11:338-51.
4. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001;69: 135-44.
5. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A 2004;101:15949-54.
6. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445:776-80.
7. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-7.
8. Kuhnert F, Kirshner JR, Thurston G. Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc Cell 2011;3:20.
9. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168-77.
10. Jimeno A, LoRusso P, Strother RM, Diamond J, Plato L, Younger A, et al. A phase I first-in-human study of enoticumab (REGN421/SAR153192), a fully human Delta-like ligand 4 (Dll4) directed monoclonal antibody in patients with advanced solid tumors. J Clin Oncol 31, 2013 (suppl; abstr 2502).
11. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444:1083-7.
12. Jakobsson L, Bentley K, Gerhardt H. VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans 2009;37:1233-6.
13. Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, et al. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol 2010;176:2019-28.
14. Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, et al. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer 2009;101:1749-57.
15. Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, et al. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res 2011;71:6030-9.
16. Zhang JX, Cai MB, Wang XP, Duan LP, Shao Q, Tong ZT, et al. Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma. Med Oncol 2013;30:390.
17. Chen HT, Cai QC, Zheng JM, Man XH, Jiang H, Song B, et al. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer. Ann Surg Oncol 2012;19 (Suppl 3): S464-74.
18. Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011;71: 1520-5.
19. Egloff AM, Grandis JR. Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. Clin Cancer Res 2012;18: 5188-95.
20. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 2012;30:2307-13.
21. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 2012;30: 2348-53.
22. Cubillo A, Jameson M, Grande E, Parnis F, Grimison P, Cooray P, et al. A phase Ib study of demcizumab (anti-Dll4) with gemcitabine in patients with first line locally advanced ormetastatic pancreatic cancer. Mol Cancer Ther 2013;12 (11 Suppl):B78.
23. Luxan G, Casanova JC, Martinez-Poveda B, Prados B, D'Amato G, Mac-Grogan D, et al. Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. Nat Med 2013;19: 193-201.
24. Saravanakumar M, Devaraj H. Notch signalling in cardiovasculogenesis: insight into their role in early cardiovascular development. Mol Biol Rep 2013;40:3537-47.
25. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010;463:E6-7.
26. Yan M. Therapeutic promise and challenges of targeting DLL4/NOTCH1. Vasc Cell 2011;3:17.
27. Liu Z, Turkoz A, Jackson EN, Corbo JC, Engelbach JA, Garbow JR, et al. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest 2011;121:800-8.
28. Nakamura T, Tsuchiya K, Watanabe M. Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J Gastroenterol 2007;42:705-10.
29. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
30. Kang M, Jiang B, Xu B, Lu W, Guo Q, Xie Q, et al. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. Cancer Lett 2013;330:11-21.